Methylene blue is having a moment. Patients are hearing claims about brain fog, focus, memory, and mitochondrial health. But how much of that is backed by evidence?
In this episode, NatMed editors Jeff Langford, Andrea Stafford, and Kelly Daniels break down what methylene blue is, what the evidence shows, and why safety may be a bigger concern than many patients realize.
Questions we answer:
- What is methylene blue, and why is it trending now?
- Does it actually help with focus, memory, or brain fog?
- What are the key safety risks and drug interactions clinicians should know about?
- Which patients should avoid methylene blue entirely?
We also cover:
- Why methylene blue is not a natural supplement
- Product quality and regulatory concerns
- SSRIs, serotonin syndrome, and other interaction risks
- How to counsel patients when the hype exceeds the evidence
🏷️ Our listeners can get 10% off a new or upgraded subscription with code natmed1026b at checkout.
NatMed / TRC Healthcare Editor Hosts:
- Jeff Langford PharmD, BCPS, BCCP (Managing Clinical Editor)
- Andrea Stafford, PharmD (Assistant Editor)
- Kelly Daniels, BA (News Editor & Associate Content Manager)
CE Information:
This podcast is sourced from the NatMed August Newsletter. To claim CE credit, subscribers should read the newsletter and click “Take the CE Quiz” link to take the quiz.
The clinical resources mentioned during the podcast are part of a subscription to NatMed:
- 🌱 NatMed Pro
- 💊 TRC Healthcare
- Newsletter
- Monograph: Methylene Blue
Email us: [email protected]
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Natural Medicines: Evidence in Practice is a production of TRC Healthcare.
Click here to listen to all podcast episodes.
Listen Now:
Transcript:
This transcript is automatically generated.
00:00:04 Kelly Daniels
You’ve probably had this happen.
00:00:05 Kelly Daniels
A patient comes in, shows you their phone and asks, have you heard about this?
00:00:10 Kelly Daniels
Today, that this is methylene blue.
00:00:13 Jeff Langford
Well, welcome back to Natural Medicines: Evidence in Practice.
00:00:16 Jeff Langford
I’m Jeff Langford, a pharmacist and managing editor at NatMed.
00:00:20 Andrea Stafford
And I’m Andrea Stafford, a pharmacist and assistant editor.
00:00:23 Kelly Daniels
And I’m Kelly Daniels, content production manager.
00:00:26 Jeff Langford
And on this show, we’re going to cut through trends and marketing to bring practical, evidence-based guidance for real patient conversations.
00:00:34 Andrea Stafford
And today we’re walking through Methylene Blue, what it is, why patients are hearing about it, and how to approach it in practice.
00:00:42 Kelly Daniels
Quick note, CE credit is available for our podcast through our monthly NatMed newsletter.
00:00:46 Kelly Daniels
Check the show notes for how to claim it.
00:00:48 Jeff Langford
So Kelly, help us set the stage here.
00:00:50 Jeff Langford
What’s driving interest in Methylene Blue right now?
00:00:54 Kelly Daniels
Honestly, this one has a lot going for it from a trend perspective.
00:00:58 Kelly Daniels
First, it’s the visual hook.
00:00:59 Kelly Daniels
It’s bright blue. You’ve probably seen it online.
00:01:02 Kelly Daniels
People are posting videos of themselves taking it and their mouths are turning bright blue.
00:01:07 Kelly Daniels
So it’s super memorable and people are curious.
00:01:09 Kelly Daniels
And then there’s also the fact that it sounds scientific.
00:01:12 Kelly Daniels
You hear about claims about mitochondrial support, antioxidant effects and brain performance.
00:01:18 Andrea Stafford
And I have to admit that bright blue color is appealing.
00:01:22 Andrea Stafford
It definitely piqued my interest.
00:01:24 Andrea Stafford
And this combination of that visual novelty and scientific sounding language is what makes this feel interesting and credible at the same time.
00:01:33 Andrea Stafford
So it ends up sitting in this space we’ve talked about before with sea moss, where something sounds exciting and promising, but maybe the evidence isn’t quite there yet.
00:01:44 Jeff Langford
Yeah, and I think that’s exactly why we want to have a conversation about this one today.
00:01:48 Jeff Langford
But Andrea, help us think through the backstory.
00:01:52 Jeff Langford
What is methylene blue?
00:01:54 Andrea Stafford
And it’s been around for a while, methylene blue is a synthetic blue dye with a long history.
00:02:00 Andrea Stafford
It was first used as a textile dye in 1876, and by the 1890s, it was explored as an anti-malarial treatment, and it’s been used to stain microorganisms to help diagnose certain infections.
00:02:15 Andrea Stafford
But today, it’s an FDA-approved prescription medication primarily used intravenously to treat methemoglobinemia, a condition where hemoglobin loses its ability to effectively bind and transport oxygen.
00:02:30 Andrea Stafford
So you might be asking, well, what’s changed?
00:02:33 Andrea Stafford
And that’s this context.
00:02:35 Andrea Stafford
It’s moved outside the clinical setting and into conversations about improved cognitive function, its antioxidant activity, and optimizing mitochondrial function, which these are very different claims from its approved indications and those original uses.
00:02:51 Jeff Langford
Yeah, cool background, Andrea.
00:02:52 Jeff Langford
It’s kind of interesting for the medical nerd in me to hear that evolution from like synthetic dye to medical use to FDA drug to supplement.
00:03:01 Jeff Langford
And that shift in context that you talk about is really where things can get a little bit murky because as a supplement, methylene blue lives in a regulatory gray space.
00:03:10 Jeff Langford
It is an FDA approved drug or it’s available in that form.
00:03:15 Jeff Langford
But the products sold in this wellness space aren’t FDA approved.
00:03:18 Jeff Langford
And they can vary in quality greatly.
00:03:22 Jeff Langford
So there are different formulations in purity.
00:03:25 Jeff Langford
Some of what you see out there is an industrial grade, not pharmaceutical grade product.
00:03:29 Jeff Langford
Methylene Blue is also, as kind of a side trivia note, an antifungal or anti-parasitic agent that’s used in aquariums.
00:03:37 Jeff Langford
That form should not be ingested by humans.
00:03:39 Jeff Langford
So there’s a lot that could crowd the shelves or crowd a search results page when you look for methylene blue products.
00:03:46 Andrea Stafford
And Jeff, I think this is where this like regulatory gap and these concerning formulations make this clinically tricky to navigate.
00:03:55 Andrea Stafford
Because in practice, we associate methylene blue with a controlled, monitored setting, IV administration, a specific diagnosis and a clear indication.
00:04:04 Andrea Stafford
Not really a patient self-administering drops that they ordered online.
00:04:08 Andrea Stafford
And by the time it comes up in conversation, it’s already kind of been reframed and it doesn’t sound like a prescription drug at all, but rather this natural supplement to optimize health.
00:04:19 Jeff Langford
Yeah, and I’m going to key in on one word you said there, Andrea, and that’s natural.
00:04:23 Jeff Langford
I think it’s really important to point out this isn’t natural.
00:04:26 Jeff Langford
This goes back to your history.
00:04:28 Jeff Langford
It’s synthetic.
00:04:29 Jeff Langford
This was synthesized in the 1800s using kind of these coal tar derivatives.
00:04:33 Jeff Langford
So it is a synthetic product, but it does sit in this wellness space.
00:04:37 Jeff Langford
So that’s important for us to be aware of and certainly just to help square away perceptions for folks as well.
00:04:44 Andrea Stafford
Yeah, and that’s a good clarification, Jeff.
00:04:46 Kelly Daniels
Yeah, that’s so interesting because a lot of health influencers online are touting this as a natural alternative product, but it’s actually a synthetic product, which is a little bit scary.
00:04:57 Kelly Daniels
And they’re also, as you say, Jeff, a lot of sources, different quality issues that come up, possible risks.
00:05:03 Kelly Daniels
What about evidence of benefit, Andrea?
00:05:05 Andrea Stafford
And that’s a fair question, Kelly.
00:05:08 Andrea Stafford
The honest answer is the evidence doesn’t really support these claims.
00:05:12 Andrea Stafford
Although mechanistically it sounds promising, methylene blue is thought to donate electrons to the mitochondrial electron transport chain, which, in theory, could support cellular energy production in the brain.
00:05:25 Andrea Stafford
And the early data is interesting.
00:05:27 Andrea Stafford
Animal models have shown cognitive enhancing effects, and there is a small human study that suggested neurological benefit during these attention and short-term memory tasks, though notably no effect on cerebral blood flow was observed, and these findings were based on this functional MRI imaging.
00:05:46 Andrea Stafford
So the mechanism, while plausible, that alone doesn’t mean there’s a clinical benefit.
00:05:52 Jeff Langford
And we kind of turn the page from some of those lab type studies that you were talking about, Andrea, and look at research in humans becomes limited and really inconsistent, even for some of those most studied areas of interest like Alzheimer’s disease.
00:06:07 Jeff Langford
In that case, for example, there’s one trial in patients with moderate Alzheimer’s disease, and they did find some moderate cognitive improvement at a specific dose, like 138 milligrams per day.
00:06:17 Jeff Langford
But that same trial found no benefit when we used a lower dose or a higher dose.
00:06:24 Jeff Langford
Some other studies still in that same, looking at the same general disease state, looked at a slightly modified form of methylene blue and one of them found no reduction in disease progression.
00:06:36 Jeff Langford
The other one found a modest benefit.
00:06:38 Jeff Langford
But these trials really had some methodological limitations, like one of them had no placebo group.
00:06:44 Jeff Langford
And then when we try to kind of back that focus out a little bit and look at it more broadly in the cognitive space, like for general enhancement of cognitive function, memory or age-related cognitive decline, there’s really not reliable clinical evidence for those more general use cases.
00:07:02 Jeff Langford
So it’s really difficult for us to translate some of the specific and limited data in Alzheimer’s disease out to a broader use for cognitive enhancement in healthy folks.
00:07:13 Andrea Stafford
And this is a pattern, Jeff, that shows up with other conditions as well, whether that’s depression or fatigue.
00:07:19 Andrea Stafford
That answer is kind of the same.
00:07:20 Andrea Stafford
That mechanism is plausible, but the data is lacking or limited or in these very specific populations and conditions, meaning no strong clinical evidence to support kind of routine use in a healthy population.
00:07:33 Kelly Daniels
For a patient, that’s a really different message than what they’re seeing online.
00:07:37 Kelly Daniels
This boost brain’s function sounds super simple, but what the research says is much more nuanced, as you said.
00:07:44 Kelly Daniels
So there’s some signal in people with Alzheimer’s, but even that evidence is mixed.
00:07:49 Kelly Daniels
And really none of this actually applies to the everyday healthy person who’s just trying to get a little bit of a cognitive boost.
00:07:57 Jeff Langford
Yeah, Kelly, so I think that population distinction is super important.
00:08:00 Jeff Langford
There is the difference between it working for a disease state to try to reverse or mitigate a process that has happened versus preventing a disease state from ever occurring.
00:08:12 Jeff Langford
And we really don’t have data supporting that more general use.
00:08:15 Jeff Langford
And that’s before we turn the page and think about the safety profile, which is where the conversation can get a little bit complicated, Andrea.
00:08:22 Andrea Stafford
Yes, because that safety profile does shape how we approach a recommendation here.
00:08:28 Andrea Stafford
And we want to start with the patient.
00:08:29 Andrea Stafford
There are specific conditions where methylene blue should be avoided altogether.
00:08:35 Jeff Langford
Yeah, so G6PD deficiency is one of those examples in patients with this specific condition.
00:08:42 Jeff Langford
There is the concern that methylene blue can’t be converted to its active form and then accumulates, leading to blood cell breakdown and ultimately hemolytic anemia.
00:08:51 Jeff Langford
So while data on oral methylene blue is still uncertain, we would suggest avoiding it definitely for patients with that condition.
00:09:00 Andrea Stafford
And it’s similar for kidney and liver disease as well.
00:09:04 Andrea Stafford
They’re kind of on this list since methylene blue is renally excreted and hepatically metabolized.
00:09:09 Andrea Stafford
Impaired function in either organ can delay clearance and raise the risk of adverse effects.
00:09:15 Andrea Stafford
So again, avoidance is recommended until more information is available.
00:09:20 Jeff Langford
And we have some drug interactions that can be a concern for patients.
00:09:24 Jeff Langford
So tell me a little bit about what you have dug into there, Andrea.
00:09:27 Andrea Stafford
Yes. So mechanistically, methylene blue acts as this anticholinergic and serotonergic agent.
00:09:35 Andrea Stafford
So interactions with drugs or supplements in either of those classes are going to be a concern.
00:09:41 Jeff Langford
Yeah, and these are frequent flyers in routine medical use.
00:09:45 Jeff Langford
So for example, patients on serotonergic meds like SSRI or SNRI antidepressants, That would be like sertraline, paroxetine, fluoxetine are common examples.
00:09:55 Jeff Langford
Or supplements with serotonergic properties like St. John’s Wort.
00:09:59 Jeff Langford
They are at increased risk for serotonergic adverse effects.
00:10:02 Jeff Langford
That could include serotonin syndrome.
00:10:05 Jeff Langford
And notably with IV use of methylene blue, fatalities have been reported when it’s been combined with serotonergic med.
00:10:12 Jeff Langford
So it is a serious concern.
00:10:14 Jeff Langford
This has not been documented with oral use, but it definitely remains something that we want to keep very top of mind when we think about this supplement.
00:10:22 Andrea Stafford
And Jeff, that does sound really alarming, but I think this is where NatMed’s interaction framework is really helpful.
00:10:29 Andrea Stafford
Can you give some additional insight into that kind of interaction and that rating?
00:10:34 Jeff Langford
Yeah, sure. So we build interaction ratings based on the likelihood of the interaction occurring as well as the potential severity of it.
00:10:43 Jeff Langford
And we blend all of that data to give kind of a red, yellow, green message out to users about how to manage that.
00:10:50 Jeff Langford
So in this case, the severity rating is high because it could be potentially very, very serious.
00:10:56 Jeff Langford
The occurrence with oral methylene blue we rank as possible because it is theoretical in this case with the oral product.
00:11:03 Jeff Langford
And blending that together, we ultimately assign a moderate rating, meaning be careful with this combination.
00:11:09 Jeff Langford
But I definitely think this is a case that we would skew to a very high level of caution based on that theoretical risk.
00:11:17 Kelly Daniels
So it sounds like you’ve got thin evidence on one side and real safety questions on the other.
00:11:22 Kelly Daniels
So methylene blue isn’t exactly a yes or no answer.
00:11:25 Kelly Daniels
It has to be a conversation.
00:11:28 Jeff Langford
Yeah, and these conversational answers that we need to have, Kelly, this is a space we land in a lot of times with these supplements where it’s not really clear cut.
00:11:35 Jeff Langford
And I absolutely agree with that.
00:11:37 Jeff Langford
If these questions are coming up in your practice and you need information to drive these conversations, NatMed Pro is designed to support them.
00:11:44 Andrea Stafford
And you can check evidence, safety, and interactions quickly, all in one place, like Jeff just demonstrated with interactions.
00:11:51 Kelly Daniels
So you’re not relying on memory you’re confirming in real time.
00:11:54 Andrea Stafford
Plus, NatMed offers CE options and our monthly newsletter.
00:11:59 Andrea Stafford
And listeners can save 10% with code natmed1026 at checkout.
00:12:03 Andrea Stafford
Links are in the show notes.
00:12:06 Kelly Daniels
Okay, let’s walk through a quick patient scenario to bring this together.
00:12:10 Kelly Daniels
Imagine a 30-year-old female patient comes in.
00:12:12 Kelly Daniels
She’s been seeing methylene blue all over social media, and she really wants to give it a try.
00:12:18 Kelly Daniels
How does that conversation start?
00:12:21 Jeff Langford
Right away I want to understand the patient’s goals.
00:12:24 Jeff Langford
I saw it online, tells me not so much.
00:12:26 Jeff Langford
I need to know what she’s hoping to get out of using methylene blue.
00:12:31 Kelly Daniels
Okay, so she tells you it’s for focus and brain fog.
00:12:35 Andrea Stafford
Okay. That kind of gives us a good idea of the direction we would need to go for counseling regarding the evidence around maybe focus and brain fog.
00:12:44 Andrea Stafford
But before diving into evidence, I want to make sure that this is safe for our patient.
00:12:48 Andrea Stafford
I want to know what medication she’s currently taking.
00:12:52 Kelly Daniels
Well, this patient says she’s taking sertraline as well as prenatal vitamins, but she does mention that she’s in the process of stopping the antidepressant.
00:13:01 Jeff Langford
Okay. So that’s a lot to address before we even dive into the evidence.
00:13:05 Jeff Langford
But we do hear in the scenario you’re painting out, Kelly, first, we’re getting definitely clued into that potential drug interaction with an SSRI or sertraline and that risk of serotonin syndrome.
00:13:16 Jeff Langford
As we said earlier, serious concern, we definitely have to discuss that.
00:13:20 Andrea Stafford
And the prenatal vitamins also raise kind of an immediate question.
00:13:24 Andrea Stafford
Is this patient hoping to conceive?
00:13:26 Andrea Stafford
If so, we need to be upfront that there’s really no reliable safety data on oral methylene blue supplementation in pregnancy.
00:13:34 Andrea Stafford
And animal studies have shown fetal toxicity at higher doses.
00:13:38 Kelly Daniels
Okay, so for this case, let’s say she’s not trying to conceive and she’s committed to discontinuing the sertraline.
00:13:45 Kelly Daniels
Once those concerns are addressed, what else does she need to know?
00:13:49 Jeff Langford
I think, Kelly, here’s where we probably do go back to that evidence that Andrea helped unpack for us.
00:13:54 Jeff Langford
And I’d say, here, we want to share with the patient that there isn’t good evidence to support the use case that she’s considering.
00:14:02 Jeff Langford
Even if we think about for Alzheimer’s disease, the evidence is mixed.
00:14:05 Jeff Langford
And for this kind of healthy adult looking to sharpen focus or clear some brain fog, there’s really no reliable clinical trial supporting that use.
00:14:14 Kelly Daniels
Okay, so the bottom line is this trend is really way ahead of the evidence, and right now there are risks that outweigh any possible benefit.
00:14:22 Andrea Stafford
I agree, Kelly.
00:14:23 Andrea Stafford
I think that’s where I would land too.
00:14:24 Andrea Stafford
But if the patient still wants to try it, because sometimes that happens in real world, I would counsel on those safety considerations, like ensuring an appropriate washout from her antidepressant, and then also choosing a methylene blue product from a reliable source that uses pharmacy grade product.
00:14:42 Jeff Langford
I think that patient scenario highlighted some of the key takeaways from this one.
00:14:46 Jeff Langford
With methylene blue, the evidence may sound compelling, but it’s still limited or lacking really for general use.
00:14:52 Andrea Stafford
And the bigger issue for many patients isn’t whether it works.
00:14:55 Andrea Stafford
It’s whether it fits safely within what they’re already taking, as we just saw in that patient case.
00:15:02 Kelly Daniels
And from the patient side, this is a great example of how something that looks scientific can still carry risks that they don’t expect.
00:15:08 Andrea Stafford
So this is one where checking those interactions, slowing down that conversation really makes an impact.
00:15:15 Jeff Langford
Yeah, Methylene Blue is a good reminder that not every trending product fits into the usual supplement conversation.
00:15:21 Andrea Stafford
And sometimes that question isn’t just, does it work?
00:15:24 Kelly Daniels
It’s, does it even belong in this patient’s plan?
00:15:28 Jeff Langford
To claim CE, follow the instructions linked in our show notes.
00:15:31 Jeff Langford
We’ve included links to the monograph, the newsletter article, and other tools we discussed so you can bring these tips straight to practice.
00:15:38 Kelly Daniels
Also in the August newsletter, we cover some other interesting and timely topics, including a review of commonly used lactation supplements and a discussion on biotin beauty claims.
00:15:47 Andrea Stafford
So follow and subscribe to this show in your podcast app so new episodes land automatically.
00:15:53 Jeff Langford
Thanks for listening to Natural Medicines: Evidence in Practice.
00:15:56 Jeff Langford
It’s evidence, not hype.
00:15:57 Andrea Stafford
And we’ll see you next month.
Natural Medicines: Evidence in Practice
